npj Breast Cancer (Dec 2021)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
- Khalid El Bairi,
- Harry R. Haynes,
- Elizabeth Blackley,
- Susan Fineberg,
- Jeffrey Shear,
- Sophia Turner,
- Juliana Ribeiro de Freitas,
- Daniel Sur,
- Luis Claudio Amendola,
- Masoumeh Gharib,
- Amine Kallala,
- Indu Arun,
- Farid Azmoudeh-Ardalan,
- Luciana Fujimoto,
- Luz F. Sua,
- Shi-Wei Liu,
- Huang-Chun Lien,
- Pawan Kirtani,
- Marcelo Balancin,
- Hicham El Attar,
- Prerna Guleria,
- Wenxian Yang,
- Emad Shash,
- I-Chun Chen,
- Veronica Bautista,
- Jose Fernando Do Prado Moura,
- Bernardo L. Rapoport,
- Carlos Castaneda,
- Eunice Spengler,
- Gabriela Acosta-Haab,
- Isabel Frahm,
- Joselyn Sanchez,
- Miluska Castillo,
- Najat Bouchmaa,
- Reena R. Md Zin,
- Ruohong Shui,
- Timothy Onyuma,
- Wentao Yang,
- Zaheed Husain,
- Karen Willard-Gallo,
- An Coosemans,
- Edith A. Perez,
- Elena Provenzano,
- Paula Gonzalez Ericsson,
- Eduardo Richardet,
- Ravi Mehrotra,
- Sandra Sarancone,
- Anna Ehinger,
- David L. Rimm,
- John M. S. Bartlett,
- Giuseppe Viale,
- Carsten Denkert,
- Akira I. Hida,
- Christos Sotiriou,
- Sibylle Loibl,
- Stephen M. Hewitt,
- Sunil Badve,
- William Fraser Symmans,
- Rim S. Kim,
- Giancarlo Pruneri,
- Shom Goel,
- Prudence A. Francis,
- Gloria Inurrigarro,
- Rin Yamaguchi,
- Hernan Garcia-Rivello,
- Hugo Horlings,
- Said Afqir,
- Roberto Salgado,
- Sylvia Adams,
- Marleen Kok,
- Maria Vittoria Dieci,
- Stefan Michiels,
- Sandra Demaria,
- Sherene Loi,
- The International Immuno-Oncology Biomarker Working Group
Affiliations
- Khalid El Bairi
- Department of Medical Oncology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Mohammed Ist University
- Harry R. Haynes
- Department of Cellular Pathology, Great Western Hospital
- Elizabeth Blackley
- Division of Research, Peter MacCallum Cancer Centre
- Susan Fineberg
- Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine
- Jeffrey Shear
- Chief Information Officer, WISS & Company, LLP and President J. Shear Consulting, LLC–Ardsley
- Sophia Turner
- ICPV, Independent Cancer Patient Voice
- Juliana Ribeiro de Freitas
- Department of Pathology and Legal Medicine, Medical School of the Federal University of Bahia
- Daniel Sur
- Department of Medical Oncology, University of Medicine “I. Hatieganu”
- Luis Claudio Amendola
- Brazilian Society of Oncology
- Masoumeh Gharib
- Faculty of Medicine, Mashhad University of Medical Sciences
- Amine Kallala
- Hopital Charles Nicolle
- Indu Arun
- Department of Histopathology, Tata Medical Center
- Farid Azmoudeh-Ardalan
- Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences
- Luciana Fujimoto
- Pathology and Legal Medicine, Amazon Federal University
- Luz F. Sua
- Department of Pathology and Laboratory Medicine, Fundacion Valle del Lili, and Faculty of Health Sciences, Universidad ICESI
- Shi-Wei Liu
- Sichuan Cancer Hospital
- Huang-Chun Lien
- Department of Pathology, National Taiwan University Hospital
- Pawan Kirtani
- Department of Histopathology, Manipal Hospitals Dwarka
- Marcelo Balancin
- Department of Pathology, Faculty of Medicine, University of São Paulo
- Hicham El Attar
- Apc labs - Annasr Pathology Center
- Prerna Guleria
- Army Hospital Research and Referral, Delhi Cantt
- Wenxian Yang
- Aginome Scientific Pte Ltd
- Emad Shash
- Breast Cancer Comprehensive Center, National Cancer Institute, Cairo University
- I-Chun Chen
- Department of Oncology, National Taiwan University Cancer Center
- Veronica Bautista
- Department of Pathology, Breast Cancer Center FUCAM
- Jose Fernando Do Prado Moura
- Centro de Pesquisas Clinicas do IMIP
- Bernardo L. Rapoport
- The Medical Oncology Centre of Rosebank
- Carlos Castaneda
- Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas
- Eunice Spengler
- Departmento de Patologia, Hospital Universitario Austral
- Gabriela Acosta-Haab
- Department of Pathology, Hospital de Oncología Maria Curie
- Isabel Frahm
- Department of Pathology, Sanatorio Mater Dei
- Joselyn Sanchez
- Department of Research, Instituto Nacional de Enfermedades Neoplasicas
- Miluska Castillo
- Department of Research, Instituto Nacional de Enfermedades Neoplasicas
- Najat Bouchmaa
- Institute of Biological Sciences, Mohammed VI Polytechnic University (UM6P)
- Reena R. Md Zin
- Department of Pathology, Faculty of Medicine, UKM Medical Centre
- Ruohong Shui
- Department of Pathology, Fudan University Cancer Center
- Timothy Onyuma
- Kenyatta National Hospital
- Wentao Yang
- Department of Pathology, Fudan University Cancer Center
- Zaheed Husain
- Praava Health
- Karen Willard-Gallo
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles
- An Coosemans
- Laboratory of Tumour Immunology and Immunotherapy, Department of Oncology, KU Leuven
- Edith A. Perez
- Department of Hematology/Oncology, Mayo Clinic
- Elena Provenzano
- Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust
- Paula Gonzalez Ericsson
- Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
- Eduardo Richardet
- Clinical Oncology Unit, Instituto Oncológico Córdoba
- Ravi Mehrotra
- India Cancer Research Consortium-ICMR, Department of Health Research
- Sandra Sarancone
- Department of Pathology, Laboratorio QUANTUM
- Anna Ehinger
- Department of Clinical Genetics and Pathology, Skåne University Hospital, Lund University
- David L. Rimm
- Department of Pathology, Yale School of Medicine
- John M. S. Bartlett
- Diagnostic Development, Ontario Institute for Cancer Research
- Giuseppe Viale
- Department of Pathology, Istituto Europeo di Oncologia IRCCS, and University of Milan
- Carsten Denkert
- Institute of Pathology, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg and Philipps-Universität Marburg
- Akira I. Hida
- Department of Pathology, Matsuyama Shimin Hospital
- Christos Sotiriou
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles
- Sibylle Loibl
- German Breast Group
- Stephen M. Hewitt
- Laboratory of Pathology, National Cancer Institute, NIH
- Sunil Badve
- Department of Pathology and Laboratory Medicine, Indiana University
- William Fraser Symmans
- Department of Pathology, The University of Texas M.D. Anderson Cancer Center
- Rim S. Kim
- National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology
- Giancarlo Pruneri
- Department of Pathology, RCCS Fondazione Istituto Nazionale Tumori and University of Milan, School of Medicine
- Shom Goel
- Division of Research, Peter MacCallum Cancer Centre
- Prudence A. Francis
- Sir Peter MacCallum Department of Oncology, University of Melbourne
- Gloria Inurrigarro
- Department of pathology Sanatorio Mater Dei
- Rin Yamaguchi
- Department of Pathology and Laboratory Medicine, Kurume University Medical Center, Kurume
- Hernan Garcia-Rivello
- Servicio de Anatomía Patológica, Hospital Italiano de Buenos Aires
- Hugo Horlings
- Division of Pathology, The Netherlands Cancer Institute
- Said Afqir
- Department of Medical Oncology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Mohammed Ist University
- Roberto Salgado
- Division of Research, Peter MacCallum Cancer Centre
- Sylvia Adams
- Perlmutter Cancer Center, New York University Medical School
- Marleen Kok
- Divisions of Medical Oncology, Molecular Oncology & Immunology, The Netherlands Cancer Institute
- Maria Vittoria Dieci
- Department of Surgery, Oncology and Gastroenterology, University of Padova
- Stefan Michiels
- Service de Biostatistique et d’Epidémiologie, Gustave Roussy, Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer
- Sandra Demaria
- Department of Radiation Oncology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Sherene Loi
- Division of Research, Peter MacCallum Cancer Centre
- The International Immuno-Oncology Biomarker Working Group
- DOI
- https://doi.org/10.1038/s41523-021-00346-1
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 17
Abstract
Abstract The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.
